Introduction {#H1-1-ZOI180042}
============

Adolescent and young adult oncology has recently become a subspecialty of cancer research.^[@zoi180042r1],[@zoi180042r2]^ Adolescent and young adult cancer survivors, defined as those in whom cancer was diagnosed when they were aged 15 to 39 years,^[@zoi180042r2],[@zoi180042r3],[@zoi180042r4]^ differ from younger and older patients with cancer in the biology, epidemiology, and clinical outcomes of cancer^[@zoi180042r5]^ and are at risk for long-term morbidity associated with their cancer or cancer treatment. Cancer is 7-fold more frequent in adolescents and young adults than in children younger than 15 years,^[@zoi180042r3],[@zoi180042r4]^ with the pattern of late effects depending on the age at diagnosis.^[@zoi180042r6]^ Most data on the long-term sequelae in cancer survivors at a young age are derived from studies of childhood cancer survivors.^[@zoi180042r3],[@zoi180042r7]^ Survivors of cancer in adolescence and young adulthood, their relatives, and the treating clinicians also require information on the long-term outcomes of treatment.

Common late effects in this population of survivors include second primary cancers, cardiovascular and pulmonary complications, neurological complications, and endocrine and gonadal disorders.^[@zoi180042r6]^ These are stages of life with many transitions in terms of education, employment, social relations, relocations, and family formation.^[@zoi180042r3]^ Endocrine late effects, with hormonal disturbances and gonadal dysfunction, could have many physical and social consequences for cancer survivors. Several studies have assessed the late effects of treatment for site-specific cancers in the age range of adolescents and young adults,^[@zoi180042r3]^ including testicular cancer,^[@zoi180042r8]^ Hodgkin lymphoma,^[@zoi180042r9],[@zoi180042r10],[@zoi180042r11]^ and breast cancer,^[@zoi180042r12]^ reporting increased risks for hypogonadism, hypothyroidism, and premature menopause in survivors. However, there is little information about endocrine late effects in survivors of other cancers in this age group. We report the results of, to our knowledge, the first large-scale population-based study of all hospital contacts for endocrine diseases, which includes more than 32 000 adolescent and young adult 1-year cancer survivors and 5-fold as many population comparisons.

Methods {#H1-2-ZOI180042}
=======

Survivors and Comparison Participants {#H2-1-ZOI180042}
-------------------------------------

The basic cohort of adolescent and young adult cancer survivors was identified from the Danish Cancer Registry,^[@zoi180042r13]^ which contains records of all incident cases of cancer nationwide since 1943. Each cancer record includes the personal identification number, date of diagnosis, and type of cancer. Cancers were classified according to modified *International Classification of Diseases, Seventh Revision*codes between 1943 and 1977 and according to the *International Classification of Diseases, Tenth Revision* (*ICD*-*10*) for diagnosis and the *International Classification of Diseases for Oncology, Third Revision* for morphology and topography from 1978 onward.^[@zoi180042r13]^ The unique personal identification number assigned to all Danish citizens since the start of the Civil Registration System on April 2, 1968, incorporates date of birth and sex and permits accurate linkage among Danish administrative and medical registers.^[@zoi180042r14],[@zoi180042r15]^ From 1976 through 2009, 38 670 individuals aged 15 to 39 years were registered with a first primary cancer in the Danish Cancer Registry. These individuals were the basis for the 1-year survivor cohort to observe in the Danish National Patient Registry, which is a nationwide registry initiated on January 1, 1977 (eFigure 1 in the [Supplement](#note-ZOI180042-1-s){ref-type="supplementary-material"}). We followed the Strengthening the Reporting of Observational Studies in Epidemiology ([STROBE](http://www.equator-network.org/reporting-guidelines/strobe/)) reporting guideline. This study was approved by the Danish Data Protection Agency. Patient consent was waived because the data set did not include any identifiable sensitive personal data or identification number.

The comparison cohort was identified through the Civil Registration System.^[@zoi180042r14],[@zoi180042r15]^ For each survivor, we randomly chose 5 cancer-free comparison participants of the same sex and year of birth who were alive on the date of diagnosis of cancer in the survivor, resulting in 193 350 comparisons. In both cohorts, we excluded individuals who had died or emigrated during the first year after cancer diagnosis or a corresponding date for the comparison participants. This resulted in a cohort of 34 448 survivors and 192 254 comparison participants (eFigure 1 in the [Supplement](#note-ZOI180042-1-s){ref-type="supplementary-material"}).

Hospital Contacts for Endocrine Disease {#H2-2-ZOI180042}
---------------------------------------

For both survivors and comparison participants, we identified all hospital admissions and outpatient visits with a primary or supplementary discharge diagnosis of endocrine disease (*International Classification of Diseases, Eighth Revision* \[*ICD-8*\] codes 240-258 and *ICD-10* codes E01-E35 and E89) in the Danish Patient Registry.^[@zoi180042r16]^ The registry includes information on all hospital admissions for somatic disease since 1977, including outpatient visits since 1995. Diagnoses made by general practitioners were not included. Diagnostic information was coded according to *ICD-8* until 1993 and thereafter according to *ICD-10*.^16^ We identified hospital admissions for endocrine diseases defined in chapter 3 of *ICD-8* and chapter 4 of *ICD-10* and excluded nutritional and metabolic diseases, including metabolic syndrome, as we consider these diseases multifactorial and strongly associated with lifestyle or other factors rather than with cancer treatment. Further, metabolic syndrome was introduced in *ICD-10* only recently. We also excluded congenital endocrine disorders, disorders of puberty, and diseases of the thymus, which occur primarily in childhood.

We excluded patients in whom an endocrine disease had been diagnosed before the cancer or a corresponding date for comparison participants as well as survivors with chromosome abnormalities or congenital endocrine malformations (eFigure 1 in the [Supplement](#note-ZOI180042-1-s){ref-type="supplementary-material"}) registered in the Danish Patient Registry. We also excluded patients with a pituitary tumor because of the direct risk for endocrine dysfunction. After these exclusions, 32 548 one-year survivors and 188 728 population comparison participants remained for analysis.

Follow-up {#H2-3-ZOI180042}
---------

Follow-up for endocrine disease late effects started 1 year after cancer diagnosis and on a corresponding date for the equivalent comparison participants. Follow-up ended on the date of death, emigration, second primary cancer diagnosis in survivors or first primary cancer diagnosis in comparison participants, or the closing date (December 31, 2010), whichever occurred first. For participants with more than 1 hospital contact for a particular endocrine disease, only the first record was retained, which was presumed to be the date of diagnosis.

Statistical Analysis {#H2-4-ZOI180042}
--------------------

Risk analyses were performed for any endocrine disease and for 9 main diagnostic categories and 26 subcategories. We compared the rates of first hospital contact for survivors with expected rates derived from the comparison cohort. We estimated hospitalization rate ratios (RRs) with 95% confidence intervals as the ratio of observed to expected hospitalization rates for each defined disease entity separately and by censoring for competing events. We used Fieller theorem, assuming that the observed number of first hospital contacts followed a Poisson distribution.^[@zoi180042r17]^ We calculated absolute excess risks (AERs)---the additional risk of adolescent and young adult cancer survivors for a hospital contact for an endocrine disease---as the difference between the observed and the expected first hospitalization rate for endocrine disease per 100 000 person-years of follow-up, with 95% confidence intervals. Risk analyses were performed for the total cohort of survivors and separately in subcohorts of survivors who had 1 of the 10 most frequent cancers occurring in adolescence and young adulthood. Analyses were stratified according to sex, age at cancer diagnosis, calendar period of cancer diagnosis, and attained age at diagnosis of the endocrine disease. The association of survivor demographic characteristics (sex, age, year of diagnosis, and type of cancer) with the risk for any endocrine disease was investigated in a multivariate analysis within the survivor cohort. A Cox proportional hazards model was used to estimate hospitalization rate hazard ratios for any endocrine disease. All tests were 2-sided likelihood ratio tests with a *P* value less than .05 considered statistically significant. We estimated the cumulative incidence of overall and selected endocrine diseases, with death as a competing risk^[@zoi180042r18]^ and age as the underlying timescale using left truncation. Statistical analyses were conducted using SAS software version 9.3 (SAS Institute Inc) and R statistical computing software version 3.2.3 (R Foundation), and the Survival and Design packages were used.

Results {#H1-3-ZOI180042}
=======

We studied 32 548 adolescent and young adult 1-year cancer survivors (14 021 \[43.1%\] male) in the Danish Patient Registry for 379 157 person-years (median \[range\] time, 10 \[0-34\] years) and 188 728 population comparisons (82 669 \[43.8%\] male) for 2 958 994 person-years (median \[range\] time, 15 \[0-34\] years). A total of 2129 survivors (6.5%) had at least 1 hospital contact for an endocrine disease, while 1232.0 (3.8%) were expected, yielding a statistically significantly increased RR of 1.73 (95% CI, 1.65-1.81) ([Table 1](#zoi180042t1){ref-type="table"}). The overall observed and expected rates of hospitalization for endocrine diseases were 561.5 and 324.9 per 100 000 person-years, respectively, resulting in an AER of 236.6 (95% CI, 212-261) per 100 000 person-years (ie, a new excess case of endocrine disease in 237 of 100 000 survivors for each additional year of follow-up) ([Table 1](#zoi180042t1){ref-type="table"}). The risk for any endocrine disease compared with risk in the background population was higher in male survivors (RR, 2.41; 95% CI, 2.23-2.61) than in female survivors (RR, 1.46; 95% CI, 1.38-1.55), reflecting lower background rates of endocrine diseases in males. A younger age at cancer diagnosis was associated with a higher RR and a higher AER for any endocrine disease ([Table 1](#zoi180042t1){ref-type="table"}). The risk for hospital contact for endocrine diseases decreased with time since cancer diagnosis, with an RR of 2.60 (95% CI, 2.39-2.82) for 1 to 4 years since diagnosis and an RR of 1.45 (95% CI, 1.34-1.57) for 10 to 19 years since diagnosis ([Table 1](#zoi180042t1){ref-type="table"}).

###### Numbers of First Hospital Contacts for Endocrine Disease by Patient Factors

  Characteristic                                    Hospital Contacts, No.   Survivors at Risk, Person-Years   All Endocrine Disease                                                    
  ------------------------------------------------- ------------------------ --------------------------------- ----------------------- -------- ---------------------- -------- ------- ---------------------
  Total[^b^](#zoi180042t1n2){ref-type="table-fn"}   32 548                   379 157                           2129                    1232.0   1.73 (1.65 to 1.81)    561.5    324.9   237 (212 to 261)
  Sex                                                                                                                                                                                   
  Male                                              14 021                   167 616                           826                     342.5    2.41 (2.23 to 2.61)    492.8    204.3   288 (254 to 323)
  Female                                            18 527                   211 541                           1303                    889.5    1.46 (1.38 to 1.55)    616.0    420.5   195 (160 to 230)
  Attained age, y                                                                                                                                                                       
  16-19                                             1369                     2128                              17                      2.0      8.43 (4.14 to 17.16)   798.8    94.8    704 (321 to 1087)
  20-29                                             9363                     34 812                            197                     49.9     3.95 (3.31 to 4.70)    565.9    143.4   423 (342 to 503)
  30-39                                             26 930                   121 540                           603                     261.3    2.31 (2.10 to 2.53)    496.1    215.0   281 (240 to 322)
  40-49                                             21 463                   145 634                           728                     470.5    1.55 (1.43 to 1.68)    499.9    323.1   177 (139 to 215)
  50-59                                             9997                     60 499                            410                     331.3    1.24 (1.12 to 1.37)    677.7    547.6   130 (62 to 199)
  60-69                                             3539                     14 152                            166                     113.5    1.46 (1.24 to 1.72)    1172.9   802.1   371 (187 to 555)
  ≥70                                               285                      391                               8                       3.5      2.29 (1.08 to 4.87)    2044.2   890.9   1153 (−287 to 2594)
  Age at cancer diagnosis, y                                                                                                                                                            
  15-19                                             1838                     21 014                            139                     34.4     4.04 (3.41 to 4.78)    661.5    163.8   498 (387 to 608)
  20-24                                             3328                     42 100                            248                     88.7     2.80 (2.46 to 3.17)    589.1    210.7   378 (305 to 452)
  25-29                                             5920                     73 297                            362                     200.0    1.81 (1.63 to 2.01)    493.9    272.9   221 (170 to 272)
  30-34                                             8939                     104 625                           568                     349.1    1.63 (1.50 to 1.77)    542.9    333.7   209 (164 to 254)
  35-39                                             12 523                   138 121                           812                     559.9    1.45 (1.35 to 1.56)    587.9    405.3   183 (142 to 224)
  Calender year for cancer diagnosis                                                                                                                                                    
  1975-1989                                         12 411                   217 562                           1036                    717.9    1.44 (1.35 to 1.54)    476.2    330.0   146 (116 to 176)
  1990-2009                                         20 137                   161 595                           1093                    514.2    2.13 (2.00 to 2.26)    676.4    318.2   358 (318 to 399)
  Years since cancer diagnosis                                                                                                                                                          
  1-4                                               32 548                   109 682                           616                     237.1    2.60 (2.39 to 2.82)    561.6    216.1   345 (301 to 390)
  5-9                                               23 874                   100 059                           421                     254.0    1.66 (1.50 to 1.83)    420.8    253.9   167 (126 to 208)
  10-19                                             17 642                   121 623                           649                     448.8    1.45 (1.34 to 1.57)    533.6    369.0   165 (123 to 206)
  \>20                                              8325                     47 793                            443                     292.2    1.52 (1.38 to 1.67)    926.9    611.3   315 (229 to 402)

Abbreviations: AER, absolute excess risk; RR, hospitalization rate ratio.

Observed and expected numbers of first hospital contacts for endocrine disease of any type among 32 548 adolescent and young adult 1-year cancer survivors in Denmark, 1976 to 2009.

According to Statistics Denmark, 8% of the Danish population has immigrated from non-Western countries.

Survivors had significantly increased risks for 8 of 9 main diagnostic groups of endocrine disease and 18 of 26 subcategories ([Table 2](#zoi180042t2){ref-type="table"}). The highest RRs were seen for testicular hypofunction (75.12; 95% CI, 45.99-122.70), ovarian hypofunction (14.65; 95% CI, 8.29-25.86), and pituitary hypofunction (11.14; 95% CI, 8.09-15.34). Diseases of the thyroid gland, testicular dysfunction, and diabetes were the leading reasons for hospital contacts (38.0%, 17.1%, and 14.4% of total AER, respectively).

###### First Hospital Contacts for Endocrine Disease by Diagnostic Categories or Diagnoses[^a^](#zoi180042t2n1){ref-type="table-fn"}

  Category of Endocrine Disease and Diagnostic Entity (*ICD-10*Code)[^b^](#zoi180042t2n2){ref-type="table-fn"}   First Hospital Contacts, No.[^c^](#zoi180042t2n3){ref-type="table-fn"}   RR (95% CI)   AER (95% CI)              \% of Total AER   
  -------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ------------- ------------------------- ----------------- ------
  Diseases of the thyroid gland (E01, E02, E03.2-E03.9, E04-E07, E35.0, and E89.0)                               1039                                                                     654.9         1.59 (1.48 to 1.70)       100 (83 to 117)   38.0
  Goiter, nontoxic (E01 and E04)                                                                                 394                                                                      325.6         1.21 (1.09 to 1.35)       18 (7 to 28)      
  Thyrotoxicosis (E05)                                                                                           279                                                                      225.0         1.24 (1.09 to 1.41)       14 (5 to 23)      
  Hypothyroidism (E02, E03.2-E03.9, and E89.0)                                                                   444                                                                      152.4         2.91 (2.61 to 3.25)       75 (64 to 85)     
  Thyroiditis (E06)                                                                                              55                                                                       46.8          1.17 (0.88 to 1.56)       2 (−2 to 6)       
  Other diseases of the thyroid gland (E07 and E35.0)                                                            14                                                                       15.5          0.91 (0.52 to 1.58)       0 (−2 to 2)       
  Diabetes (E10-E14 and E89.1)                                                                                   660                                                                      511.1         1.29 (1.19 to 1.40)       38 (25 to 52)     14.4
  Type 1 (E10)                                                                                                   264                                                                      188.4         1.40 (1.23 to 1.60)       19 (11 to 28)     
  Type 2 (E11)                                                                                                   520                                                                      408.4         1.27 (1.16 to 1.40)       29 (16 to 41)     
  Other types (E12-E14 and E89.1)                                                                                146                                                                      89.4          1.63 (1.37 to 1.95)       14 (8 to 21)      
  Disorders of pancreatic internal secretion other than diabetes (E15-E16)                                       49                                                                       41.1          1.19 (0.88 to 1.61)       2 (−2 to 6)       0.8
  Diseases of parathyroid glands (E20-E21, and E89.2)                                                            93                                                                       33.8          2.75 (2.17 to 3.49)       15 (10 to 20)     5.7
  Hyperparathyroidism (E21.0-E21.3)                                                                              48                                                                       26.4          1.82 (1.33 to 2.49)       6 (2 to 9)        
  Hypoparathyroidism (E20-E89.2)                                                                                 49                                                                       7.9           6.19 (4.24 to 9.04)       10 (7 to 14)      
  Other diseases of parathyroid glands (E21.4 and E21.5)                                                         1                                                                        0.4           2.53 (0.26 to 24.42)      0 (0 to 1)        
  Diseases of pituitary gland (E22-E23 and E89.3)                                                                122                                                                      22.1          5.53 (4.38 to 6.99)       25 (20 to 31)     9.5
  Pituitary hyperfunction (E22)                                                                                  19                                                                       12.0          1.58 (0.96 to 2.59)       2 (0 to 4)        
  Pituitary hypofunction (E23.0-E23.3 and E89.3)                                                                 93                                                                       8.4           11.14 (8.09 to 15.34)     22 (17 to 26)     
  Other diseases of pituitary gland (E23.6 and E23.7)                                                            23                                                                       2.8           8.28 (4.58 to 14.96)      5 (3 to 8)        
  Diseases of adrenal glands (E25.8, E25.9, E26, E27, E35.1, and E89.6)                                          73                                                                       18.25         4.00 (3.01 to 5.31)       14 (10 to 18)     5.3
  Adrenocortical hyperfunction (E25.8, E25.9, E26, and E27.0)                                                    12                                                                       5.5           2.17 (1.14 to 4.13)       2 (0 to 3)        
  Adrenomedullary hyperfunction (E27.5)                                                                          14                                                                       1.6           8.66 (4.02 to 18.68)      3 (1 to 5)        
  Adrenal hypofunction (E27.1-E27.4 and E89.6)                                                                   43                                                                       7.7           5.58 (3.76 to 8.28)       9 (6 to 12)       
  Other diseases of adrenal glands (E27.8, E27.9, and E35.1)                                                     6                                                                        4.1           1.46 (0.61 to 3.51)       0 (−1 to 2)       
  Ovarian dysfunction (E28 and E89.4)[^d^](#zoi180042t2n4){ref-type="table-fn"}                                  74                                                                       35.4          2.09 (1.61 to 2.70)       10 (5 to 14)      3.8
  Ovarian hypofunction (E28.3 and E89.4)                                                                         35                                                                       2.4           14.65 (8.29 to 25.86)     8 (5 to 11)       
  Other diseases of the ovaries (E28.2, E28.8, and E28.9)                                                        39                                                                       31.5          1.24 (0.88 to 1.74)       2 (−1 to 5)       
  Testicular dysfunction (E29 and E89.5)[^d^](#zoi180042t2n4){ref-type="table-fn"}                               182                                                                      4.5           40.24 (27.91 to 58.01)    45 (38 to 52)     17.1
  Testicular hypofunction (E29.1 and E89.5)                                                                      175                                                                      2.3           75.12 (45.99 to 122.70)   44 (37 to 51)     
  Other diseases of testis (E29.8 and E29.9)                                                                     10                                                                       2.4           4.22 (1.95 to 9.16)       2 (0 to 4)        
  Other diseases of endocrine glands (E24, E31, E34, E35.8, E89.8, and E89.9)                                    70                                                                       14.7          4.78 (3.54 to 6.45)       14 (10 to 18)     5.3
  Cushing syndrome (E24)                                                                                         10                                                                       4.4           2.29 (1.13 to 4.66)       1 (0 to 3)        
  Other endocrine diseases (E34, E35.8, E89.8, and E89.9)                                                        59                                                                       9.9           5.94 (4.22 to 8.36)       12 (9 to 16)      

Abbreviations: AER, absolute excess risk; *ICD-10*, *International Classification of Diseases, Tenth revision*; RR, hospitalization rate ratio.

Excluded diagnoses are nutritional and metabolic diseases (E40-E88 and E90), metabolic syndrome (E888C), congenital endocrine disorders (E00, E03.0, E03.1, and E25), disorders of puberty (E30), and diseases of thymus (E32).

Endocrine diseases of which there were fewer than 5 cases are not included even if the RR was high and/or statistically significant.

Observed and expected numbers of first hospital contacts for endocrine disease among 32 548 adolescent and young adult 1-year cancer survivors in Denmark, by 9 main diagnostic categories and 26 subcategories or diagnoses.

Numbers and rates for ovarian and testicular diseases are calculated for the entire cancer survivor and comparison cohorts even though these disorders occur only in women and men, respectively.

Analyses by sites of cancer revealed the highest RRs for any endocrine disease for survivors of leukemia (RR, 3.97; 95% CI, 3.10-5.09), Hodgkin lymphoma (RR, 3.06; 95% CI, 2.62-3.57), and brain cancer (RR, 3.03; 95% CI, 2.53-3.64) ([Table 3](#zoi180042t3){ref-type="table"}; eFigure 2 in the [Supplement](#note-ZOI180042-1-s){ref-type="supplementary-material"}). Survivors of Hodgkin lymphoma had a particularly high excess risk for hypothyroidism (AER, 362 per 100 000 person-years; 95% CI, 280-443 per 100 000 person-years). Brain cancer survivors were at increased risk for a broad spectrum of endocrine diseases, comprising diseases of the pituitary and thyroid glands as well as diabetes. For survivors of the most common cancers among adolescents and young adults, the risks for hospital contact for endocrine disease were significantly increased for testicular cancer (RR, 2.50; 95% CI, 2.25-2.78) and breast cancer (RR, 1.16; 95% CI, 1.02-1.32), whereas the risks among survivors of malignant melanoma (RR, 1.08; 95% CI, 0.95-1.24) and cervical cancer (RR, 0.94; 95% CI, 0.82-1.07) were similar to those of the comparison cohort ([Table 3](#zoi180042t3){ref-type="table"}).

###### Endocrine Disease by 10 Most Frequent Cancer Sites[^a^](#zoi180042t3n1){ref-type="table-fn"}

  Site of Cancer and Endocrine Disease[^b^](#zoi180042t3n2){ref-type="table-fn"}   Hospital Contacts, No.   RR (95% CI)                 AER (95% CI) per 100 000 Person-Years
  -------------------------------------------------------------------------------- ------------------------ --------------------------- ---------------------------------------
  Brain cancer (n = 1895)                                                          116                      3.03 (2.53 to 3.64)         490 (357 to 623)
  Pituitary hypofunction                                                           40                       112.01 (75.55 to 166.07)    244 (168 to 320)
  Other pituitary diseases                                                         15                       104.23 (55.19 to 196.85)    90 (44 to 137)
  Pituitary hyperfunction                                                          5                        11.28 (4.57 to 27.84)       28 (1 to 54)
  Thyrotoxicosis                                                                   14                       2.24 (1.32 to 3.79)         47 (2 to 92)
  Diabetes (all types)                                                             32                       2.05 (1.44 to 2.90)         100 (32 to 168)
  Leukemia (n = 944)                                                               63                       3.97 (3.10 to 5.09)         755 (506 to 1004)
  Ovarian hypofunction                                                             13                       236.74 (121.17 to 462.56)   200 (91 to 309)
  Testicular hypofunction                                                          8                        155.26 (69.59 to 346.42)    122 (37 to 207)
  Pituitary hypofunction                                                           8                        52.56 (25.28 to 109.27)     121 (35 to 206)
  Type 2 diabetes                                                                  17                       3.46 (2.14 to 5.57)         187 (62 to 313)
  Hodgkin lymphoma (n = 1713)                                                      165                      3.06 (2.62 to 3.57)         509 (393 to 624)
  Testicular hypofunction                                                          5                        27.67 (10.53 to 72.72)      21 (2 to 40)
  Hypothyroidism                                                                   87                       14.89 (11.93 to 18.59)      362 (280 to 443)
  Diabetes, other and unspecified                                                  11                       2.68 (1.48 to 4.87)         30 (2 to 58)
  Goiter                                                                           32                       2.46 (1.73 to 3.49)         83 (35 to 132)
  Type 2 diabetes                                                                  37                       2.00 (1.45 to 2.77)         81 (29 to 134)
  Non-Hodgkin lymphoma (n = 1201)                                                  66                       1.86 (1.46 to 2.37)         237 (113 to 361)
  Ovarian hypofunction                                                             9                        134.34 (58.76 to 307.11)    67 (23 to 112)
  Testicular hypofunction                                                          6                        57.88 (23.58 to 142.07)     44 (8 to 81)
  Pituitary hypofunction                                                           5                        17.89 (7.19 to 44.48)       36 (3 to 69)
  Hypothyroidism                                                                   14                       3.78 (2.23 to 6.42)         78 (22 to 134)
  Testis (n = 5503)                                                                393                      2.50 (2.25 to 2.78)         305 (254 to 356)
  Testicular hypofunction                                                          148                      134.71 (82.75 to 219.29)    186 (156 to 216)
  Adrenal hypofunction                                                             21                       21.31 (11.14 to 40.77)      25 (14 to 37)
  Testicular dysfunction, other and unspecified                                    8                        7.23 (3.14 to 16.60)        9 (2 to 16)
  Thyrotoxicosis                                                                   24                       2.21 (1.45 to 3.39)         17 (4 to 29)
  Type 1 diabetes                                                                  73                       1.58 (1.24 to 2.00)         34 (12 to 55)
  Type 2 diabetes                                                                  143                      1.50 (1.27 to 1.78)         61 (30 to 91)
  Ovary (n = 775)                                                                  44                       1.14 (0.85 to 1.54)         56 (−78 to 189)
  Diabetes, other and unspecified                                                  7                        4.18 (1.98 to 8.86)         53 (1 to 104)
  Breast (n = 4654)                                                                237                      1.16 (1.02 to 1.32)         71 (7 to 136)
  Diseases of the thyroid gland                                                    172                      1.28 (1.10 to 1.49)         80 (26 to 135)
  Malignant melanoma (n = 5133)                                                    225                      1.08 (0.95 to 1.24)         30 (−21 to 82)
  Goiter                                                                           82                       1.44 (1.16 to 1.80)         43 (13 to 73)
  Colon (n = 596)                                                                  14                       0.68 (0.40 to 1.14)         −111 (−232 to 11)
  Cervix (n = 3987)                                                                224                      0.94 (0.82 to 1.07)         −26 (−80 to 28)
  Type 2 diabetes                                                                  73                       1.31 (1.03 to 1.65)         31 (0 to 61)

Abbreviations: AER, absolute excess risk, RR, hospitalization rate ratio.

Only endocrine diseases for which the RR had a lower 95% confidence limit of 1 or greater and AERs with a lower 95% confidence limit of 0 or greater were included. Endocrine disease categories of which there were fewer than 5 cases, however, were not included, even if the RR was high and/or statistically significant.

Sample size indicate number of survivors.

When the survivors were stratified by period of treatment, the RR of hospital contact for endocrine disease for those diagnosed during the period of 1975 to 1989 was 1.44 (95% CI, 1.35-1.54), whereas the corresponding risk for those diagnosed during the period of 1990 to 2009 was 48% higher (RR, 2.13; 95% CI, 2.00-2.26) ([Table 1](#zoi180042t1){ref-type="table"}).

Overall, RRs and AERs diminished with age ([Table 1](#zoi180042t1){ref-type="table"} and [Figure](#zoi180042f1){ref-type="fig"}). The risk for diabetes increased markedly after age 50 years for both survivors and comparison participants, while the RR and AER for hypothyroidism were highest in the age group 20 to 39 years. The vast majority of cases of pituitary hypofunction were diagnosed before the age of 30 years.

![Hospitalization Rates for Any Endocrine Disease and Selected Endocrine Diseases\
Age-specific observed and expected hospitalization rates for any endocrine disease and selected endocrine diseases among 32 548 adolescent and young adult 1-year cancer survivors.](jamanetwopen-1-e180349-g001){#zoi180042f1}

The cumulative risk of survivors for any endocrine disease by age 30 years was 6.6% (95% CI, 6.5%-6.6%) and by age 60 years was 12.5% (95% CI, 12.2%-12.7%), while the cumulative risk of comparison participants by age 30 years was 1.7% (95% CI, 1.7%-1.7%) and by age 60 years was 11.4% (95% CI, 11.2%-11.6%). Survivors of Hodgkin lymphoma were at considerably high risk for hypothyroidism, with a cumulative risk of 9.6% (95% CI, 7.5%-11.6%) by age 60 years; the corresponding cumulative risk for comparisons was 1.4% (95% CI, 1.3%-1.4%).

In a multivariate analysis, significant variation in the risk of the survivor cohort for any endocrine disorder was found by sex, age at diagnosis, year of diagnosis, and type of cancer ([Table 4](#zoi180042t4){ref-type="table"}). The adjusted hazard ratio of females for any endocrine disorder was 1.85 (95% CI, 1.65-2.09; *P* \< .001) compared with males. In line with our findings in [Table 1](#zoi180042t1){ref-type="table"}, the adjusted hazard ratios decreased significantly with increasing age at cancer diagnosis (ages 35-39 vs 15-19 years: adjusted HR, 0.55; 95% CI, 0.43-0.71; *P* \< .001) and increased in the most recent calendar period of diagnosis (1990-2009 vs 1975-1989: adjusted HR, 1.97; 95% CI, 1.78-2.18; *P* \< .001). The adjusted hazard ratios according to cancer site matched the corresponding RR estimates compared with the general population ([Table 3](#zoi180042t3){ref-type="table"} and [Table 4](#zoi180042t4){ref-type="table"}; eFigure 2 in the [Supplement](#note-ZOI180042-1-s){ref-type="supplementary-material"}); ie, in both analyses, survivors of leukemia and Hodgkin lymphoma had higher risks for endocrine disease than survivors of brain cancer, whereas survivors of cancers at other sites had lower risks.

###### Adjusted Hospitalization Rate Ratios for Endocrine Disease in a Within-Survivor Cohort Analysis

  Characteristic                                             First Hospitalizations, No.   Adjusted HR (95% CI)   *P* Value
  ---------------------------------------------------------- ----------------------------- ---------------------- -----------
  Sex                                                                                                             \<.001
  Male                                                       826                           1 \[Reference\]        NA
  Female                                                     1303                          1.85 (1.65-2.09)       \<.001
  Age at cancer diagnosis, y                                                                                      \<.001
  15-19                                                      139                           1 \[Reference\]        NA
  20-24                                                      248                           0.89 (0.70-1.12)       .32
  25-29                                                      362                           0.67 (0.53-0.85)       .001
  30-34                                                      568                           0.63 (0.50-0.81)       \<.001
  35-39                                                      812                           0.55 (0.43-0.71)       \<.001
  Calendar period of cancer diagnosis, y                                                                          \<.001
  1975-1989                                                  1036                          1 \[Reference\]        NA
  1990-2009                                                  1093                          1.97 (1.78-2.18)       \<.001
  Site of cancer[^a^](#zoi180042t4n1){ref-type="table-fn"}                                                        \<.001
  Leukemia (n = 944)                                         63                            1.36 (1.00-1.85)       .05
  Hodgkin lymphoma (n = 1713)                                165                           1.05 (0.83-1.33)       .70
  Brain cancer (n = 1895)                                    116                           1 \[Reference\]        NA
  Testicular cancer (n = 5503)                               393                           0.92 (0.74-1.15)       .45
  Non-Hodgkin lymphoma (n = 1201)                            66                            0.69 (0.51-0.93)       .02
  Breast cancer (n = 4654)                                   237                           0.48 (0.38-0.61)       \<.001
  Ovarian cancer (n = 775)                                   44                            0.45 (0.32-0.64)       \<.001
  Malignant melanoma (n = 5133)                              225                           0.43 (0.34-0.54)       \<.001
  Cervical cancer (n = 3987)                                 224                           0.39 (0.31-0.49)       \<.001
  Colon cancer (n = 596)                                     14                            0.28 (0.16-0.49)       \<.001

Abbreviations: HR, hazard ratio; NA, not applicable.

Sample sizes indicate number of survivors.

Discussion {#H1-4-ZOI180042}
==========

This nationwide, population-based cohort study showed that adolescent and young adult cancer survivors were at 73% higher risk for endocrine disease than the background population. The dominating endocrine diseases were thyroid diseases, testicular dysfunction, and diabetes. A particularly high AER for hypothyroidism was observed in Hodgkin lymphoma survivors. Treatment for Hodgkin lymphoma includes irradiation to the thyroid region; previous reviews concluded that half of Hodgkin lymphoma survivors who were irradiated subsequently experienced thyroid disease,^[@zoi180042r10],[@zoi180042r19]^ and the reported risk increased with radiation dose. Alkylating chemotherapy and irradiation increased the risk for testicular dysfunction in a dose-dependent manner.^[@zoi180042r10],[@zoi180042r19]^ In this study, brain cancer survivors had a broad spectrum of endocrine diseases, some of which might be secondary to hypothalamic and pituitary dysfunction. We found particularly high RRs and AERs for pituitary diseases in brain cancer survivors based on 40 observations of hypopituitarism, 5 observations of hyperpituitarism, and 15 observations of other pituitary diseases in 1895 brain cancer survivors. These numbers were lower than those in a British follow-up study of 56 adult nonpituitary brain cancer survivors who received radiation therapy at ages 21 to 45 years.^[@zoi180042r20]^ Hypopituitarism was reported in 41% of survivors, and the risk was associated with radiation dose but not with age at radiation, sex, or chemotherapy.^[@zoi180042r20]^

In this study, the risks for endocrine diseases were highest in leukemia survivors. In a study by Tauchmanovà et al,^[@zoi180042r21]^ in preparation for bone marrow transplantation, some patients with leukemia underwent total body irradiation, which resulted in exceptionally high risks for gonadal dysfunction (95% of women and 47% of men), thyroid dysfunction (46%), and adrenal abnormalities (10%).

We found a 40-fold increased risk for testicular dysfunction. Testicular damage is common in men receiving chemotherapy, and men receiving cytotoxic chemotherapy had a significantly lower testosterone level than healthy controls in a study of men with cancer diagnosed at a mean age of 28.6 years.^[@zoi180042r22]^ Older age at cancer diagnosis and treatment was negatively associated with testosterone level, and testosterone levels were negatively correlated with fasting glucose, insulin, and body fat mass. As an example of adverse health effects of untreated endocrine diseases, we found increased risk of diabetes in testicular cancer survivors, ovarian cancer survivors, and cervical cancer survivors, which might be related to sex hormone deficiencies. Associations between hypogonadism and men with type 2 diabetes are well described, and the relationship is bidirectional.^[@zoi180042r23]^ Type 1 diabetes may be caused by direct damage to the pancreas. A questionnaire-based survey of late effects in cervical cancer survivors showed significantly increased risk for diabetes in women treated with radiotherapy but not in those treated by surgery or by chemotherapy and surgery.^[@zoi180042r24]^

Of testicular cancer survivors, breast cancer survivors, malignant melanoma survivors, and cervical cancer survivors, which are the most common cancers in the cohort, only testicular cancer survivors and breast cancer survivors had significantly increased risk for hospital contact for endocrine disease. To our knowledge, no previous studies have evaluated the risk of endocrine diseases specifically for survivors of these cancers diagnosed in adolescence and young adulthood.

The within-cohort analysis showed that sex modified the risk for endocrine diseases, with female survivors having the highest risks. The difference in the RRs of male and female survivors might reflect the sex differences seen in the general population or biological differences between men and women (eg, female patients appeared to be more vulnerable to adverse effects of cancer treatment than males, perhaps as a result of differences in oxidative stress and body composition).^[@zoi180042r25]^

The patients with the most recent diagnoses of cancer (1990-2009) had a significantly higher risk for endocrine diseases than those with diagnoses before 1990. Surveillance bias might be more likely in the latest period, but the higher risk is more likely to be because of changes in treatment protocols and survival. Survival rates have improved dramatically over many years, resulting in increased risks for late effects.

The strengths of this study include high statistical power because of the very large cohort of cancer survivors. We used nationwide health registries of high-quality dating several decades back, allowing long follow-up and virtually no loss to follow-up. To our knowledge, this is the first large-scale study of the risks for endocrine diseases after cancer in adolescence and young adulthood, with comparisons of risks for a broad range of well-defined endocrine diseases with those expected for a large, well-defined, population-based comparison cohort. Furthermore, we were able to evaluate patterns in endocrine late effects across the spectrum of cancer sites and other patient-related factors. The inclusion of all 1-year adolescent and young adult cancer survivors diagnosed since 1976 minimizes possible selection bias. Only medically verified diagnoses of endocrine diseases were included, which ensures more correct estimates than those in studies based on self-reported data.

Limitations {#H2-5-ZOI180042}
-----------

Our study had limitations. The limitations include lack of information of less severe conditions diagnosed and treated by general practitioners. Outpatient visits were included in the patient register in 1995, meaning that only the more severe cases that required hospitalization were included before that date. This results in underestimation of the number of cases. Our results might be influenced by surveillance bias, as cancer survivors are observed more closely in the health care system than the general population. This might have caused an overestimation of the risk estimates reported in this study. The Danish Cancer Registry has limited information on cancer stage and treatment, so associations between treatment factors and endocrine late effects cannot be conclusively determined.

Conclusions {#H1-5-ZOI180042}
===========

Although increased risks for a wide range of cardiovascular diseases,^[@zoi180042r26],[@zoi180042r27]^ secondary malignancies,^[@zoi180042r28],[@zoi180042r29]^ infectious diseases, and digestive diseases^[@zoi180042r29],[@zoi180042r30]^ have been reported in cancer survivors, late effects in adolescent and young adult cancer survivors have received little attention. Our study provides new, accurate, and detailed information about these survivors and important clinical information on how the risks for such late effects are modified by patient factors. This is the first step in identifying patients who are at risk for endocrine late effects so that individual profiles can be drawn up to assess the probable risk for endocrine disease. This will require prospective capture and close phenotyping of these diseases. We hope that this study will inspire investigators in future studies to determine exact associations between treatment regimens and endocrine disease and ultimately incorporate them into individual, customized treatment plans. Each future adolescent and young adult cancer patient should be offered the least deleterious treatment to ensure high quality of life after cancer while maintaining the good cure rates. Cure has become an insufficient goal.

###### 

**eFigure 1.** Flowchart of the Adolescent and Young Adult Cancer Survivor Cohort With a First Primary Cancer Diagnosed From 1976 to 2009 At Ages 15-39 Years and of Population Comparisons

**eFigure 2.** Rate Ratios for Hospital Contacts for Any Endocrine Disorder in Survivors of Cancer At the 10 Most Frequent Cancer Sites in Adolescents and Young Adults
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Click here for additional data file.
